The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 30, 2018

Filed:

Dec. 14, 2012
Applicants:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Aravive Biologics, Inc., Houston, TX (US);

Inventors:

Patrick O'Connor, Palo Alto, CA (US);

Raymond Tabibiazar, Menlo Park, CA (US);

Amato J. Giaccia, Stanford, CA (US);

Erinn Bruno Rankin, Waltham, MA (US);

Jennifer R. Cochran, Stanford, CA (US);

Douglas Jones, Cambridge, MA (US);

Mihalis Kariolis, Stanford, CA (US);

Katherine Fuh, Palo Alto, CA (US);

Yu Miao, Sunnyvale, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 16/18 (2006.01); C07K 19/00 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); A61K 45/06 (2006.01); A61K 38/10 (2006.01); C07K 16/22 (2006.01); C07K 14/705 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4703 (2013.01); A61K 38/10 (2013.01); A61K 45/06 (2013.01); C07K 14/705 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); C07K 16/40 (2013.01); C07K 19/00 (2013.01); G01N 33/5023 (2013.01); G01N 33/689 (2013.01); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2319/30 (2013.01); G01N 2500/10 (2013.01); G01N 2800/24 (2013.01); G01N 2800/245 (2013.01); G01N 2800/347 (2013.01); G01N 2800/364 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01); G01N 2800/60 (2013.01);
Abstract

Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.


Find Patent Forward Citations

Loading…